Instead, Huang's study reported that T2DM patients who switched from a dipeptidyl peptidase-4 inhibitors (DPP-4i) to a GLP-1RAs had, in addition to better glycemic control and a marked weight loss, a significant reduction in BMD [23]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.